RE:RE:RE:RE:RE:RE:CG Oncology phase 3 results impossible for TLT to beat? Incredible how CG is IPO'd at a Market Cap of $1.5 Billion US when they are at the same stage of trial as us. Their Data is excellent and will be competition. However it is a very treatment intensive solution. With up to 15-21treatments in the 1st year plus 6 treatments in the 2nd year.So 27 treatments in 2 years. Is still see this as a tie. Although they have better initial results so far ( we don't yet know the 12, 15 and 18 months data), the treatment has more restrictions for use and is more demanding for older patients given the numerous treatments involved. We have way less treatments for a very significant durable CR rate. With a possible 3rd treatment of Ruvidar, we could be very close in CR rates IMO as time will tell. At $1.5 Billion US MC, if we were given the same valuation, we would be at $6 per share Canadian. We should definitely be at least $3 in comparison IMHO. One day I hope we are due for a serious reevaluation of our SP. CG has a partnership with Merck which probably helps. When our time comes, hopefully sooner than later we should also get proper valuation.